Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | Key challenges in developing CAR-T therapy for CLL

Marco Ruella • 7 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia

Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, highlights the major obstacles to developing CAR-T for patients with chronic lymphocytic leukemia (CLL), including T cell immune dysfunction, and the highly immunosuppressive microenvironment present in these patients. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marco Ruella

4:34
Access to CAR-T in minority patients with lymphoma in the US: a retrospective analysis
Marco Ruella • 9 Apr 2024
2:44
Do biomarkers exist for predicting response to CAR T-cell therapy?
Marco Ruella • 9 Apr 2024
2:43
Resistance to CAR T-cell therapy
Marco Ruella • 9 Apr 2024
2:19
First-in-human Phase I trial of AT101, a novel anti-CD19 CAR-T, in R/R NHL
Marco Ruella • 16 Feb 2024

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals